PubRank

Todd Golub

Author PubWeight™ 79.29‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010 39.09
2 COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010 14.62
3 Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008 10.12
4 Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell 2007 2.43
5 Small-molecule inhibitors of HIF-2a translation link its 5'UTR iron-responsive element to oxygen sensing. Mol Cell 2008 2.15
6 Integrative genome comparison of primary and metastatic melanomas. PLoS One 2010 1.97
7 Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev 2010 1.95
8 Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res 2006 1.78
9 MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. Gastroenterology 2011 1.77
10 Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood 2007 1.59
11 SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell 2013 1.30
12 Respiratory failure due to differentiation arrest and expansion of alveolar cells following lung-specific loss of the transcription factor C/EBPalpha in mice. Mol Cell Biol 2006 1.21
13 Gamma interferon triggers interaction between ICSBP (IRF-8) and TEL, recruiting the histone deacetylase HDAC3 to the interferon-responsive element. Mol Cell Biol 2002 1.03
14 15-Hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3beta and a tumor suppressor in lung cancer. Cancer Res 2008 1.00
15 Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. Clin Cancer Res 2006 0.82
16 CXCR4 pathway associated with family history of melanoma. Cancer Causes Control 2013 0.76